News

News of Cell Point Web

CENTENNIAL, Colo., March 18, 2010

Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.

CENTENNIAL, Colo., June 21, 2010

Cell>Point announced today that it has submitted to the US Food and Drug Administration (FDA) an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc‐EC‐G diagnostic in assessing patients with Coronary Artery Disease (CAD).

CENTENNIAL, Colo., June 3, 2010

Cell>Point announced today that it will present clinical results for its cancer imaging agent, 99mTc-EC-G, used to assess the efficacy of chemotherapy at the 2010 Society of Nuclear Medicine Annual Meeting on June 7, 2010.

CENTENNIAL, Colo., February 10, 2010

Cell>Point announced today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for its Phase 2/3 clinical trial of99mTc-EC-G for cancer diagnostic imaging. The trial is currently underway.

Cell>Point receives approval for Beta Cell Technology patent – 6/23/2009

CENTENNIAL, Colo., June 23, 2009 – Cell>Point today announced that the U.S.P.T.O. approved its Beta Cell Technology U.S. patent application (App. No. 10/942,615). Cell>Point’s Beta Cell Technology is currently in preclinical testing at The University of Chicago Medical Center for imaging Type I Diabetes.

Cell>Point adds Steven Hanley to Board of Advisors – 6/18/2009

CENTENNIAL, Colo., June 18, 2009 – Cell>Point is pleased to announce that Steve Hanely has joined our Board of Advisors. Mr. Hanley is a former President of the Global Imaging Division of Covidien . Mr. Hanley earned his MBA and BS, Business Administration from Marquette University.

Cell>Point adds Dr. Eric Kurzweil to Board of Advisors – 9/11/2008

CENTENNIAL, Colo., September 11, 2008 – Cell>Point is pleased to announce that Eric Kurzweil, M.D., MBA has joined our Board of Advisors. Dr. Kurzweil is currently President of the Rocky Mountain Region of Pediatrix. Pediatrix, a $2.63 billion market cap company listed on the NYSE:PDX which includes more than 900 physicians nationwide. Dr. Kurzweil received his undergraduate degree from Harvard University and his medical degree from the University of Miami School of Medicine. Dr. Kurzweil earned his master’s degree of business administration from the University of Colorado.

Cell>Point establishes European subsidiary — 7|1|08

CENTENNIAL, Colo., July 1, 2008 – Cell>Point announced today that it has established a subsidiary in the Netherlands, Cell>Point Netherlands BV. Cell>Point plans to expand its operation in Europe including financial partners and European clinical trial sites for its Phase III clinical trials in 99mTc-EC-G.

Cell>Point to present at Wachovia 2008 Healthcare Conference — 1|25|08

CENTENNIAL, Colo., January 25, 2008 – Cell>Point, L.L.C. today announced that it will present at the Wachovia 2008 Healthcare Conference, which will be held January 29-31, 2008, at The Langham Hotel in Boston, Mass. Cell>Point will present Thursday, January 31 at 1:00 pm (Eastern Time) in the Palmer Room.

Diagnostic Imaging April 2007 Article — 4|18|07

Cell>Point was featured in the Diagnostic Imaging April 2007 issue “Small biopharm company hatches plan to unseat FDG” according to Terry Colip, Managing Partner of Cell>Point. To view article go to www.diagnosticimaging.com April 2007 issue.

Dr. F. David Rollo joins Cell>Point as President — 9|12|06

CENTENNIAL, Colo., September 12, 2006 Cell>Point today announced F. David Rollo, M.D., Ph.D. has joined the company as President. Dr. Rollo was formerly Chief Medical Officer of Philips Medical Systems, a global leader in diagnostic imaging systems and healthcare information technology solutions.
Cell>Point has licensed five radiopharmaceutical technology platforms from The University of Texas M.D Anderson Cancer Center. Continue reading

Cell>Point expands clinical trial for Imaging Myocardial Viability — 6|1|06

CENTENNIAL, Colo., June 1, 2006 -Cell>Point today announced it plans to start a Phase II clinical trial to evaluate the effectiveness of its 99mTc-EC-DG (Technetium-99m-Ethylenedicys-teine-Deoxyglucose) in diagnosing the presence of viable tissue in regions of the myocardium damaged by myocardial infarction or chronic coronary artery disease. Continue reading

Cell>Point named Biotech Rising Star of the Year — 11|8|05

ENGLEWOOD, Colorado – November, 8, 2005 – Cell>Point was named Biotech “Rising Star of the Year” by the Colorado BioScience Association.

Cell>Point acquires Oligosaccharide Conjugate License — 6|3|05

HOUSTON, Texas – June 3, 2005 – Cell>Point obtained the worldwide patent and technology license to Oligosaccharide Conjugates for Dual Imaging and Radio/Chemotherapy developed at The University of Texas M. D. Anderson Cancer Center. This novel technology is facilitating the development of combination modality diagnostic imaging agents and new combination radio/chemotherapeutic agents for use in oncology, cardiology, neuroendocrinology and infectious diseases. The imaging agents will be used in SPECT/CT and PET/CT. These combination agents should shorten the time the patient has to spend in the imaging session. This dual agent technology is also facilitating the development of targeted radio/chemotherapeutic agents. The objective is for the medical oncologist/radiation oncologist to be able to administer targeted radiotherapy and chemotherapy at the same time in a single dose to the patient. Since this technology also uses Cell>Point EC Technology, the combination of the two technologies should make a very versatile imaging/therapy platform.

Cell>Point featured in Aunt Minnie — 5|20|05

ENGLEWOOD,Colorado-May20,2005-Cell>Point was featured in the following Aunt Minnie article
Biotech firm Cell>Point sees promise for oncology SPECT 1/20/2005 By: Kate Madden Yee
Since PET imaging was introduced in the 1990s, its advocates have slowly but surely established a place for the technology, so much so that PET is now considered by many to be the best modality for functional oncology imaging. Continue reading